| Issuer | % of Class | Filed | ||||
|---|---|---|---|---|---|---|
| Schedule 13D · 1 security · may seek to influence control | ||||||
|
Braveheart Bio, Inc.
13D
BRVE · 10567X101
|
11.4% |
8/14/2026
Event 8/7/2026
|
||||
| AH Bio Fund IV, L.P. | 11.4% | |||||
| AH Equity Partners Bio IV, L.L.C. | 11.4% | |||||
| Marc L. Andreessen | 11.4% | |||||
| Benjamin A. Horowitz | 11.4% | |||||
Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.